■ ORIGINAL ARTICLE

Predictive significance of the prognostic nutritional index for in-stent restenosis following carotid artery stenting

Ahmet Karaduman[1], Cemalettin Yılmaz[2], Muhammet Mucahit Tiryaki[2], Ismail Balaban[1], Elnur Alizade[1], Regayip Zehir[1]

[1]Department of Cardiology, Kartal Kosuyolu Research and Education Hospital, Istanbul, Turkey
[2]Department of Cardiology, Mus State Hospital, Saltukgazi Neighborhood, Malazgirt, Mus, Turkey

Editorial
by García-Campos Losada and Raposeiras Roubin

Correspondence to:
Ahmet Karaduman, MD,
Department of Cardiology,
Kartal Kosuyolu Research and
Education Hospital,
Denizer caddesi, Cevizli Kavşağı
No. 2 Kartal, Istanbul,Turkey,
phone: +90 505 826 33 92,
e-mail:
ahmetkaradumanmd@gmail.com

ABSTRACT

Background: Malnutrition and inflammation both have important impacts on medical outcomes of individuals treated by carotid artery stenting (CAS). However, their impact on the occurrence of carotid in-stent restenosis (ISR) is not sufficiently understood.

Aims: We explored the association of immune-nutritional status, as measured by the Prognostic Nutritional Index (PNI), with ISR in individuals who had undergone CAS.

Methods: This retrospective single-center study focused on individuals diagnosed with severe carotid artery disease who were treated with CAS in the years 2016–2021 at a tertiary healthcare facility. A total of 819 patients were considered in the analysis. Their cases were subdivided into groups in line with the presence or absence of ISR as confirmed by angiography conducted after ultrasonographic follow-up assessments.

Results: In 24 months of follow-up, ISR was observed angiographically in 35 patients (4.3%). Total cholesterol (odds ratio [OR], 1.011; 95% CI [confidence interval], 1.003–1.019; $P = 0.009$), stent overlap (OR, 5.424; 95% CI, 1.026–28.670; $P = 0.047$), residual stenosis (OR, 47.930; 95% CI, 16.280–141.110; $P <0.001$), and PNI (OR, 0.846; 95% CI, 0.782–0.915; $P <0.001$) independently served as predictors of ISR. Based on the results of the receiver operating characteristic analysis, when the cut-off threshold of the PNI score was accepted as 39.5, the score could predict ISR with sensitivity of 83% and specificity of 77%. (area under the curve [AUC] 0.808; 95% CI, 0.754–0.869; $P <0.001$)

Conclusion: This research demonstrates the existence of a meaningful independent correlation between PNI and ISR in individuals treated with CAS. Malnutrition and inflammation, parameters, easily evaluated with the help of the PNI, could be considered as simple and practical indicators for ISR in cases of CAS treatment.

Key words: carotid artery disease, carotid artery stenting, in-stent restenosis, malnutrition, Prognostic Nutritional Index

INTRODUCTION

Stroke constitutes a predominant cause of both disability and mortality on a global scale. Roughly 10%–15% of ischemic stroke cases are attributable to atherosclerotic stenosis within the carotid artery [1, 2]. Carotid artery stenting (CAS), established as a practical substitute for carotid endarterectomy, has emerged as a standard therapeutic modality for managing symptomatic or asymptomatic patients with significant carotid stenosis [3]. Despite extensive evidence elucidating the long-term outcomes following CAS, explorations of the potential risk factors influencing the protracted trajectory of the condition are still insufficient [4]. However, one critical determinant impacting the enduring efficacy and safety profile of CAS is known to be in-stent restenosis (ISR). ISR may manifest at varying rates, ranging from 3.3% to 21%, within fol-

WHAT'S NEW?

The data obtained from our study indicate that the presence of malnutrition, as assessed by the Prognostic Nutritional Index, represents a risk factor for the development of in-stent restenosis following carotid artery stenting. Assessing the Prognostic Nutritional Index score of patients undergoing carotid artery stenting before non-urgent interventional procedures and administering nutritional supplements to these patients before and after the procedure may decrease the risk of developing in-stent restenosis. In addition, it may enable patients with known malnutrition to be followed more carefully by physicians.

low-up periods from 6 months to 2 years after carotid artery stent placement [5, 6]. While early restenosis after CAS is correlated with neo-intimal hyperplasia, predominantly observed within the first year, late restenosis is associated with neo-atherosclerosis [7]. Neo-atherosclerosis mirrors the pathological attributes of conventional atherosclerosis and shares common risk factors [8].

Malnutrition is another significant public health concern, impacting approximately 30% to 70% of hospitalized individuals and correlating with unfavorable outcomes across various diseases [9, 10]. Evidence suggests that malnutrition exacerbates inflammation and fosters atherosclerosis, particularly in cases of heart failure or chronic renal failure [11, 12]. Numerous scoring systems have been proposed for identifying malnutrition, the most prominent of which include the Nutritional Risk Index, Controlling Nutritional Status (CONUT) scoring system, and Prognostic Nutritional Index (PNI) [13–15]. Furthermore, a wealth of recent evidence has underscored the significant role of both inflammation and malnutrition in driving the progression of carotid artery disease [16–18]. However, there exists insufficient information regarding the predictive significance of malnutrition and inflammation in the onset of ISR in patients undergoing CAS. The present study aimed to clarify the impact of immune-nutritional status, as reflected by PNI scores, on the occurrence of carotid ISR.

MATERIAL AND METHODS

Design of the study and selection of the patient population

This retrospective research was undertaken in a single center and enrolled 819 patients who had presented at a tertiary healthcare facility with a diagnosis of atherosclerotic carotid artery disease between 2016 and 2021 and then underwent CAS. CAS was performed based on both the European Society of Cardiology guidelines and the experience of the medical team, after considering morphological and clinical data, suitability, and the lowest periprocedural risk [19]. Patients with symptomatic carotid artery stenosis who had 50%–99% stenosis and patients with asymptomatic carotid artery stenosis who had 70% or greater stenosis underwent CAS. Those 819 individuals were subsequently subdivided into two groups, an ISR group, and a non-ISR group, in light of the presence of restenosis as angiographically confirmed following ultra-

sonographic follow-up assessments. The exclusion criteria included the following: (1) insufficient data availability; (2) confirmed non-atherosclerotic arterial stenosis (for example, cerebral arteritis); (3) history of carotid endarterectomy; and (4) severe comorbidities including advanced lung, heart, and kidney diseases or malignancies expected to result in mortality during the 6-month follow-up. Demographic information, clinical profiles, and laboratory results of all participants were obtained from the hospital's electronic health records. Baseline values for laboratory parameters were obtained from a national database, reflecting the patients' status before undergoing CAS procedures. All research described here complied in full with the principles outlined in the Declaration of Helsinki and received ethical approval from the relevant hospital. In light of the retrospective nature of this case-control study, which utilized patient medical record data, the relevant ethics committee confirmed that it was not necessary to obtain written informed consent from the analyzed patients.

Definitions

ISR was characterized using digital subtraction angiography and diagnosed in the presence of ≥50% stenosis in the treated vessel, consistent with the North American Symptomatic Carotid Endarterectomy Trial guidelines. Diagnosis of hypertension was declared if systolic pressure was ≥140 mm Hg and/or diastolic pressure was ≥90 mm Hg and/or if patients used antihypertensive medications. Diagnosis of diabetes mellitus was made in line with the diagnostic criteria established by the American Diabetes Association, i.e. with fasting plasma glucose value of ≥126 mg/dl, random plasma glucose value of ≥200 mg/dl, HbA1c value of ≥6.5%, or when antidiabetic medications were used. Finally, diagnosis of hyperlipidemia was based on a total cholesterol value of >200 mg/dl, triglyceride value of >150 mg/dl, low-density lipoprotein cholesterol value of >116 mg/dl, or usage of lipid-lowering medications. Individuals who were current smokers or had a history of tobacco use were categorized as smokers.

Follow-up assessments

Patients attended regular follow-up appointments to be evaluated by duplex ultrasound in the outpatient center of the hospital at 3, 6, 12, and 24 months following their CAS procedures. All patients with suspicion of ISR underwent further evaluations *via* digital subtraction angiography

PNI and CONUT scores for malnutrition risk assessments

The PNI is a scoring system utilized to assess malnutrition risk, calculated with albumin (SA) level and lymphocyte (LYM) count *via* application of the following equation: $10 \times SA$ (g/dl) $+ 0.005 \times$ total LYM count (mm^3) [20, 21]. Patients' initial SA values, LYM counts, and total cholesterol levels were used in computing their CONUT scores. Scores of 0, 1, 2, or 3 points were assigned based on the severity of decreases in LYM counts and total cholesterol levels, while decreases in albumin levels were allocated 0, 2, 4, or 6 points.

Statistical analysis

Continuous variables that did not reflect a normal distribution were presented as median values with interquartile ranges. Categorical data were presented as numerical values accompanied by percentages. To facilitate comparisons of independent groups of continuous data, the Mann–Whitney U test or the independent samples t-test was applied, and Pearson's χ^2 test or Fisher's exact test was applied to facilitate efforts to compare groups of categorical data. Cut-off values of the variables of interest were established *via* receiver operating characteristic (ROC) curve analysis, and ROC analysis also facilitated the dichotomization of continuous variables. Univariate and multivariable models were established with logistic regression to determine variables with the power to predict ISR. For predicting ISR, a baseline logistic regression model was constructed utilizing covariates identified as possessing associations with the occurrence of ISR in univariate analysis ($P <0.05$). This model was adjusted for traditional risk factors, including sex and age. In all of these analytical procedures, two-tailed probability (P) values lower than 0.05 were recognized as signifying the presence of statistical significance. IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, US), Jamovi, or R 4.3.2 software (R Foundation, Vienna, Austria) were used in all analyses.

RESULTS

The retrospective data of 819 patients were analyzed in this study; all of these individuals had undergone CAS placement in a single center. During 24 months of follow-up, ISR was observed angiographically in 35 patients (4.3%) (Figure 1). The demographic, clinical, and angiographic data of all analyzed patients, who were subdivided into groups according to the presence or absence of ISR, are detailed in Table 1. Hypertension was more prevalent in the group without ISR ($P = 0.048$), whereas the rates of angiographically observed residual stenosis ($P <0.001$) and stent overlap ($P <0.001$) were higher in ISR patients.

Table 2 illustrates comparisons of laboratory parameters associated with the occurrence of restenosis. Among individuals who experienced ISR, values of triglycerides and non-high-density lipoprotein cholesterol were elevated, reaching statistical significance ($P <0.001$; $P = 0.006$),

whereas their LYM counts, alanine transaminase, albumin, high-density lipoprotein cholesterol, and PNI scores were lower in comparison to those who had not experienced ISR ($P = 0.007$; $P = 0.047$; $P <0.001$; $P <0.001$; $P = 0.003$ and $P <0.001$) (Figure 2).

The PNI and CONUT scores were individually added to the base model, and two further models were created as a result (Table 4: model 1 and model 2, respectively). In model 1, total cholesterol, stent overlap, residual stenosis, and PNI score independently served as predictors of ISR (OR, 1.011; 95% CI, 1.003–1.019; $P = 0.009$; OR, 5.424; 95% CI, 1.026–28.670; $P = 0.047$; OR, 47.930; 95% CI, 16.280––141.110; $P <0.001$; and OR, 0.846; 95% CI, 0.782–0.915; $P <0.001$, respectively). In model 2, total cholesterol, stent overlap, and residual stenosis independently served as predictors of ISR (OR, 1.012; 95% CI, 1.002–1.021; $P = 0.02$; OR, 4.578; 95% CI, 1.052–19.916; $P = 0.04$; and OR, 33.998; 95% CI, 13.405–86.230; $P <0.001$, respectively). However, the CONUT score proved unable to independently predict the occurrence of ISR (OR, 1.168; 95% CI, 0.897–1.521; $P = 0.25$). Based on the results of ROC analysis, when the cut-off threshold of the PNI score is 39.5, it can predict ISR with sensitivity of 83% and specificity of 77% (AUC 0.808; 95% CI, 0.754–0.869; $P <0.001$) (Figure 3).

DISCUSSION

In this retrospective study, we investigated the capability of PNI scores to predict the occurrence of ISR in individuals treated with CAS. The findings indicated that the PNI, as an indicator of immune-nutritional status, serves as an independent predictor for developing carotid ISR.

Previous studies demonstrated variability in the incidence of restenosis CAS, with reported rates ranging from 5% to 11% across different follow-up durations. The results of systematic reviews conducted by Wholey et al. [22] and Clavel et al. [23] included cumulative restenosis rates of 5.7% and 3.46%, respectively, within the first year. Our findings also confirm the relevance of ISR as a pertinent clinical issue, as it was observed in 4.03% of our study population during the 24-month follow-up period. These consistent results underscore the critical need to identify predictors of ISR to inform and optimize clinical management strategies.

A variety of studies in the literature identified various risk factors associated with ISR following CAS. One of these risk factors is stent design. Closed-cell stents, constructed with denser and more rigid materials, produce higher rates of restenosis in comparison to open-cell stents, according to multiple studies [24, 25]. However, in our study, we did not obtain a statistical difference in ISR rates between patients treated with open-cell and closed-cell stents. This discrepancy might have arisen from the relatively shorter duration of follow-up in our study compared to most of the currently available body of literature. The persistence of residual stenosis following stent placement was recognized as an independent risk factor for restenosis. This emphasizes the critical significance of employing meticulous proce-

Figure 1. Flow diagram for inclusion in the study

Abbreviations: CAS, carotid artery stenting; CEA, carotid endarterectomy; ISR, in-stent restenosis

dural techniques during CAS to minimize the possibility of residual stenosis [26, 27]. Additionally, our study showed that the presence of residual stenosis following stent placement independently increased the risk of ISR. In contrast, increasing the diameter of the post-dilatation balloon may aid in achieving maximum stent expansion and subsequently decrease the probability of long-term restenosis [28]. We identified diabetes mellitus as another independent predictor of ISR, and Achim et al. similarly stated that their diabetic patients had a higher rate of ISR compared to individuals without diabetes, with the difference reaching the level of statistical significance [29]. Yılmaz et al. [30] conducted a study investigating the relationship between ISR and various non-traditional lipid parameters such as the atherogenic index and atherogenic index of plasma in patients undergoing CAS. Their findings indicated that several non-traditional lipid parameters had the power to independently predict carotid ISR [30]. This underscores the significance of lipid profile parameters after placing a ca-

rotid artery stent in terms of both treatment and follow-up strategies. In their study, Kadoglou et al. [31] highlight that statin therapy reduces carotid plaque vulnerability not just by lowering lipid levels but also through anti-inflammatory and other pleiotropic effects. Their review suggests that statins stabilize atherosclerotic plaques by decreasing inflammation and neovascularization, as confirmed by various imaging modalities and biomarkers. This study addressed the association between malnutrition and the occurrence of ISR following CAS, which was not previously described in the literature.

Malnutrition poses a significant public health concern, even in developed nations. The PNI serves as a critical indicator of malnutrition, calculated with an equation that utilizes the patient's LYM count and SA value. Albumin values are of great significance, as hypoalbuminemia, often associated with malnutrition, serves as a reliable predictor of surgical risk and has been independently linked to various cardiovascular disorders that may include heart failure,

Table 1. Comparison of baseline clinical, demographic and periprocedural features of carotid artery stenting of study population according to in-stent restenosis

Variables	ISR (+) n = 35	ISR (−) n = 784	P-value
Age, years, median (IQR)	66.3 (59.4–71.2)	66.1 (61.2–71.3)	0.962
Sex, male, n (%)	27 (77%)	572 (72.9%)	0.407
BMI, median (IQR)	28.1 (25.5–30.2)	26.8 (24.8–29.2)	0.322
HT, n (%)	24 (68%)	650 (83%)	**0.048**
DM, n (%)	18 (51%)	321 (40.9%)	0.429
CAD, n (%)	26 (74.2%)	588 (75.0%)	0.759
HL, n (%)	26 (86.7%)	502 (73.6%)	0.110
CKD, n (%)	6 (17.1%)	132 (16.8%)	0.948
PAD, n (%)	11 (31.4%)	173 (22%)	0.303
Smoker, n (%)	25 (57.1%)	439 (56%)	0.916
Alcohol consumption, n (%)	2 (5.7%)	32 (4%)	0.647
Symptomatic stenting, n (%)	21 (71.4%)	431 (54.9%)	0.123
Contralateral disease, n (%)	28 (80%)	613 (78.1%)	0.769
Lesion type, n (%)			
Calcified lesion	22 (62.8%)	388 (49.4%)	0.134
Thrombotic lesion	8 (22.8%)	130 (16.5%)	0.368
Dissected lesion	1 (2.9%)	26 (3.3%)	0.403
Fibrotic lesion	28 (80%)	595 (75.8%)	0.524
Ulcerous lesion	5 (14.2%)	36 (5.7%)	0.062
Predilation, n (%)	1 (2.8%)	78 (9.9%)	0.076
Postdilation, n (%)	27 (77%)	608 (77.5%)	0.842
Stent overlap, n (%)	5 (14.2%)	23 (2.9%)	**<0.001**
Open-cell stent, n (%)	12 (34.2%)	182 (23.2%)	0.232
Residual stenosis, n (%)	15 (42.8%)	16 (2%)	**<0.001**
Stent length, mm, median (IQR)	35 (30–40)	30 (30–40)	0.839
Stent duration, median (IQR)	50.5 (36–57)	46 (34–57)	0.682
Dual antiplatelet usage, n (%)	13 (43.3%)	315 (46.2%)	0.759
Statin usage, n (%)	12 (40%)	252 (37%)	0.594

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; HL, hyperlipidemia; HT, hypertension; IQR, interquartile range; ISR+, in-stent restenosis; ISR–, non-in-stent restenosis; PAD, peripheric arterial disease

stroke, and coronary artery disease. Albumin's significance particularly arises from its antioxidant, anti-inflammatory, and anticoagulant activities, in addition to its well-known impact on osmotic pressure regulation [32]. Lymphopenia, marked by decreased LYM counts, correlates with the occurrence of various adverse events in cases of atherosclerotic cardiovascular disease [33]. Furthermore, elevated values of the neutrophil/LYM ratio have prognostic predictive power in the follow-up of individuals treated with coronary artery bypass grafts, with numerous studies supporting its predictive value [34]. The number of LYM, which affects the PNI value with fivefold power, also impacts this value significantly.

Initially used in cases of malignancy and gastrointestinal disorders, the PNI gradually found further applications in cardiovascular conditions [35, 36]. The PNI correlates with diminished survival rates in cases of both chronic and acute heart failure, as well as hypertrophic cardiomyopathy cases [37–39]. Moreover, it successfully predicts mortality among individuals undergoing coronary artery bypass graft placement and those with ST-segment elevation myocardial infarction or acute coronary syndrome [40, 41].

Previous research also addressed the relationships between PNI scores and both short-term and long-term prognoses after the application of CAS. For instance, Cakmak et al. [17] considered the correlation between malnutrition and major adverse events experienced within the first 30 days after such procedures. Their research demonstrated that continuous monitoring of CONUT, Nutritional Risk Index, and PNI scores allowed for the independent prediction of major adverse events within 30 days. In another study, Öcal et al. [42] considered the relationship between immune-nutritional status, reflected by the individual's PNI score, and 5-year outcomes in individuals who had undergone CAS. They demonstrated that PNI scores were able to independently predict the likelihood of both major stroke occurrence and long-term mortality in individuals undergoing CAS.

Limitations

Our study has certain limitations that require careful consideration. First, its retrospective nature and reliance on medical record data may have introduced selection and information biases. Second, the follow-up duration for patients was confined to 24 months, potentially limiting the ability to predict long-term outcomes in the context of the association between PNI and carotid ISR. Extending this investigation to multiple centers with prospective patient

Table 2. Comparison of laboratory parameters in study population according to in-stent restenosis

Variables	ISR (+)	ISR (−)	P-value
WBC, 10⁹/l, median (IQR)	8.16 (7.57–8.2)	8.08 (6.86–9.09)	0.311
NEU, 10⁹/l, median (IQR)	5.1 (4.58–5.5)	4.82 (3.78–5.9)	0.459
LYM, 10⁹/l, median (IQR)	1.76 (1.35–2.4)	2.17 (1.76–2.55)	**0.007**
MONO, 10⁹/l, median (IQR)	0.62 (0.49–0.8)	0.69 (0.54–0.88)	0.209
Hb, g/dl, median (IQR)	12.4 (11.1–14.6)	13.6 (11.8–15.2)	0.100
MCV, fl, median (IQR)	87.3 (84.2–89.6)	87.4 (83.5–90.5)	0.853
RDW, %, median (IQR)	13.4 (12.9–14.9)	13.5 (12.9–14.9)	0.919
MPV, fL, median (IQR)	10.5 (9.6–11.7)	10 (9.4–10.9)	0.119
PLT, 10⁹/l, median (IQR)	238 (203–280)	253 (218–305)	0.160
PDW, fL, median (IQR)	12.8 (10.7–15.4)	12.4 (11–14.9)	0.951
BUN, mg/dl, median (IQR)	36.3 (30.6–41.9)	37.1 (30.3–45)	0.671
Cr, mg/dl, median (IQR)	0.9 (0.84–1.22)	0.96 (0.83–1.17)	0.772
Uric acid, mg/dl, median (IQR)	5.45 (4.1–7.55)	5.6 (4.5–6.9)	0.447
Na, (mmol/dl), median (IQR)	139 (138–140)	139 (138–141)	0.331
K, mmol/dl, median (IQR)	4.55 (4.2–4.78)	4.61 (4.25–4.87)	0.380
AST, U/l, median (IQR)	17.8 (15.7–20.8)	17.2 (13.6–22)	0.327
ALT, U/l, median (IQR)	12.6 (8.72–18.2)	16.4 (12–22)	**0.047**
Tbil, mg/dl, median (IQR)	0.44 (0.32–0.49)	0.45 (0.3–0.6)	0.569
TC, mg/dl, median (IQR)	189 (146–226)	166 (140–198)	0.064
HDL cholesterol, mg/dl, median (IQR)	37 (24.7–39)	44.7 (39–51.3)	**<0.001**
TG, mg/dl, median (IQR)	272 (240–287)	151 (106–181)	**<0.001**
LDL cholesterol, mg/dl, median (IQR)	100 (50.8–142)	86.6 (64.5–121)	0.521
Non-HDL, mg/dl, median (IQR)	151 (108–193)	121 (91.6–153)	**0.006**
HbA1c, %, median (IQR)	6.2 (5.88–6.85)	6.2 (5.8–7.2)	0.834
ALB, g/dl, median (IQR)	3.9 (3.4–3.9)	4.4 (4–4.7)	**<0.001**
CRP, mg/l, median (IQR)	3.83 (2.31–11.5)	3.1 (1.14–5.7)	0.064
CONUT score, median (IQR)	1.5 (0–3)	1 (0–2)	0.078
PNI score, median (IQR)	39 (34–39)	44 (40–47)	**<0.001**

Abbreviations: ALB, albumin; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CONUT, Controlling Nutritional Status; Cr, creatinine; CRP, C-reactive protein; Hb, hemoglobin; HbA1c, glycated hemoglobin; HDL-C, high density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; LYM, lymphocytes; MCV, mean corpuscular volume; MONO, monocytes; MPV, mean platelet volume; NEU, neutrophils; non-HDL-C, non-high-density lipoprotein cholesterol; PDW, platelet distribution width; PLT, platelets; PNI, Prognostic Nutritional Index; RDW, red blood cell distribution width; Tbil, total serum bilirubin; TC, total cholesterol; TG, triglyceride; WBC, white blood cell; other — see Table 1

Table 3. Univariate logistic regression analysis for assessment of predictors of in-stent restenosis

	UNIVARIATE	
Variables	OR (95% CI)	P-value
Age, years	1.002 (0.952–1.054)	0.937
Sex	1.467 (0.590–3.646)	0.409
DM	1.360 (0.654–2.826)	0.410
HT	0.454 (0.654–2.826)	**0.055**
Smoker	1.021 (0.654–2.826)	0.956
Hemoglobin, g/dl	0.859 (0.654–2.826)	**0.067**
Lymphocytes	0.422 (0.229–0.776)	**0.006**
ALT	0.987 (0.942–1.035)	0.601
Albumin	0.177 (0.093–0.340)	**<0.001**
Total cholesterol	1.008 (1.001–1.016)	**0.032**
HDL	0.827 (0.767–0.891)	**<0.001**
Triglyceride	1.014 (1.009–1.018)	**<0.001**
Non-HDL	1.012 (1.005–1.020)	**0.002**
CONUT score	1.340 (1.103–1.626)	**0.003**
PNI score	0.841 (0.788–0.898)	**<0.001**
Ulcerous lesion	2.761 (0.788–0.898)	**0.072**
Stent overlap	5.031 (0.788–0.898)	**0.006**
Residual stenosis	36.487 (14.904–89.326)	**<0.001**

Abbreviations: CI, confidence interval; OR, odds ratio; other — see Tables 1 and 2

Figure 2. Marginal means plot showing the relationship between the probability of in-stent restenosis and Prognostic Nutritional Index

Table 4. Multivariable model 1 — including PNI score and model 2 — including CONUT score for prediction of carotid in-stent restenosis

Variables	Model 1			Model 2		
	OR	95% CI	*P*-value	OR	95% CI	*P*-value
Age, years	0.983	0.925–1.044	0.575	0.971	0.913–1.033	0.346
Sex (male)	1.203	0.404–3.585	0.740	1.391	0.494–3.912	0.532
Total cholesterol	1.011	1.003–1.019	**0.009**	1.012	1.002–1.021	**0.019**
Stent overlap	5.424	1.026–28.670	**0.047**	4.578	1.052–19.916	**0.043**
Residual stenosis	47.930	16.280–141.110	**<0.001**	33.998	13.405–86.230	**<0.001**
CONUT score				1.168	0.897–1.521	0.248
PNI score	0.846	0.782–0.915	**<0.001**			

Abbreviations: see Table 2 and 3

Figure 3. Receiver operating characteristic curves for Prognostic Nutritional Index score to predict the in-stent restenosis

Abbreviaton: AUC, area under curve

AUC: 0.808

enrollment would facilitate a more robust evaluation of the predictive power of the PNI in conjunction with carotid ISR over an extended follow-up period. Moreover, the assessment of nutritional status and malnutrition scores (PNI), although essential for patient management, was performed only once on admission. Therefore, the obtained values may not reflect changes over time. Additionally, hormonal factors, which can influence nutritional status, were not evaluated in our study. Consequently, further research employing prospective designs and larger patient cohorts is warranted to validate our findings.

CONCLUSION

The findings of this research suggest that valuable prognostic insights can be derived from routine blood testing for patients undergoing CAS. Our investigation demonstrated that the PNI was independently correlated with ISR in CAS patients. Thus, the PNI could be successfully applied as a simple and practical indicator for ISR in individuals undergoing CAS.

Article information

REFERENCES

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: Heart disease and stroke statistics — 2016 update: A report from the American Heart Association. Circulation. 2016; 133(4): 447–454, doi: 10.1161/CIR.0000000000000366, indexed in Pubmed: 26811276.
2. Levy EI, Mocco J, Samuelson RM, et al. Optimal treatment of carotid artery disease. J Am Coll Cardiol. 2008; 51(10): 979–985, doi: 10.1016/j.jacc.2007.10.052, indexed in Pubmed: 18325435.
3. Janczak D, Malinowski M, Ziomek A, et al. Carotid artery stenting versus endarterectomy for the treatment of both symptomatic and asymptomatic patients with carotid artery stenosis: 2 years' experience in a high-volume center. Adv Clin Exp Med. 2018; 27(12): 1691–1695, doi: 10.17219/acem/75902, indexed in Pubmed: 30063301.
4. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008; 358(15): 1572–1579, doi: 10.1056/NEJMoa0708028, indexed in Pubmed: 18403765.
5. Takao N, Hagiwara Y, Shimizu T, et al. Preprocedural carotid plaque echolucency as a predictor of in-stent intimal restenosis after carotid artery stenting. J Stroke Cerebrovasc Dis. 2020; 29(12): 105339, doi: 10.1016/j.jstrokecerebrovasdis.2020.105339, indexed in Pubmed: 33032020.
6. Derdeyn CP, Fiorella D, Lynn MJ, et al. Nonprocedural symptomatic infarction and in-stent restenosis after intracranial angioplasty and stenting in the SAMMPRIS trial (stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis). Stroke. 2017; 48(6): 1501–1506, doi: 10.1161/STROKEAHA.116.014537, indexed in Pubmed: 28455321.
7. Gröschel K, Riecker A, Schulz JB, et al. Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke. 2005; 36(2): 367–373, doi: 10.1161/01.STR.0000152357.82843.9f, indexed in Pubmed: 15625299.
8. Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: A final common pathway of late stent failure. J Am Coll Cardiol. 2012; 59(23): 2051––2057, doi: 10.1016/j.jacc.2011.10.909, indexed in Pubmed: 22651862.
9. Datema FR, Ferrier MB, Baatenburg de Jong RJ. Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer. Oral Oncol. 2011; 47(9): 910–914, doi: 10.1016/j.oraloncology.2011.06.510, indexed in Pubmed: 21802345.
10. Horwich TB, Kalantar-Zadeh K, MacLellan RW, et al. Albumin levels predict survival in patients with systolic heart failure. Am Heart J. 2008; 155(5): 883–889, doi: 10.1016/j.ahj.2007.11.043, indexed in Pubmed: 18440336.
11. Sciatti E, Lombardi C, Ravera A, et al. Nutritional deficiency in patients with heart failure. Nutrients. 2016; 8(7): 442, doi: 10.3390/nu8070442, indexed in Pubmed: 27455314.
12. Tsuruya K, Eriguchi M, Yamada S, et al. Cardiorenal syndrome in end-stage kidney disease. Blood Purif. 2015; 40(4): 337–343, doi: 10.1159/000441583, indexed in Pubmed: 26657922.

13. Kheirouri S, Alizadeh M. Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with cancer: A systematic review. Adv Nutr. 2021; 12(1): 234–250, doi: 10.1093/advances/nmaa102, indexed in Pubmed: 32910812.

14. Chen QJ, Qu HJ, Li DZ, et al. Prognostic nutritional index predicts clinical outcome in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Sci Rep. 2017; 7(1): 3285, doi: 10.1038/s41598-017-03364-x, indexed in Pubmed: 28607442.

15. Lin F, Xia W, Chen M, et al. A prognostic model based on nutritional risk index in operative breast cancer. Nutrients. 2022; 14(18): 3783, doi: 10.3390/nu14183783, indexed in Pubmed: 36145159.

16. Demir M, Özbek M. Impact of nutritional assessment on long-term outcomes in patients with carotid artery stenting. Int J Clin Pract. 2021; 75(10): e14637, doi: 10.1111/ijcp.14637, indexed in Pubmed: 34310821.

17. Çakmak EÖ, Öcal L, Erdoğan E, et al. Prognostic value of 3 nutritional screening tools to predict 30-day outcome in patients undergoing carotid artery stenting. Angiology. 2022; 73(3): 225–233, doi: 10.1177/00033197211040365, indexed in Pubmed: 34463144.

18. Keskin M, Öcal L, Cerşit S, et al. The predictive role of a novel risk index in patients undergoing carotid artery stenting: Systemic immune-inflammation index. J Stroke Cerebrovasc Dis. 2021; 30(9): 105955, doi: 10.1016/j.jstrokecerebrovasdis.2021.105955, indexed in Pubmed: 34242858.

19. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: The European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763–816, doi: 10.1093/eurheartj/ehx095, indexed in Pubmed: 28886620.

20. Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980; 139(1): 160–167, doi: 10.1016/0002-9610(80)90246-9, indexed in Pubmed: 7350839.

21. Bayram Z, Efe SÇ, Karagöz A, et al. Prognostic impact of nutritional indices in candidates for heart transplantation. Turk Kardiyol Dern Ars. 2022; 50(2): 92–100, doi: 10.5543/tkda.2022.21126, indexed in Pubmed: 35400629.

22. Wholey MH, Wholey M, Mathias K, et al. Global experience in cervical carotid artery stent placement. Catheter Cardiovasc Interv . 2000; 50(2): 160–167, doi: 10.1002/(sici)1522-726x(200006)50:2<160::aid-ccd2>3.0.co;2-e, indexed in Pubmed: 10842380.

23. Clavel P, Hebert S, Saleme S, et al. Cumulative incidence of restenosis in the endovascular treatment of extracranial carotid artery stenosis: a meta-analysis. J Neurointerv Surg. 2019; 11(9): 916–923, doi: 10.1136/neurintsurg-2018-014534, indexed in Pubmed: 30705056.

24. Texakalidis P, Giannopoulos S, Kokkinidis DG, et al. Effect of open- vs closed-cell stent design on periprocedural outcomes and restenosis after carotid artery stenting: A systematic review and comprehensive meta-analysis. J Endovasc Ther. 2018; 25(4): 523–533, doi: 10.1177/1526602818783505, indexed in Pubmed: 29923453.

25. Megaly M, Alani F, Cheng CI, et al. Risk factors for the development of carotid artery in-stent restenosis: Multivariable analysis. Cardiovasc Revasc Med. 2021; 24: 65–69, doi: 10.1016/j.carrev.2020.09.005, indexed in Pubmed: 32928694.

26. Xin WQ, Li MQ, Li K, et al. Systematic and comprehensive comparison of incidence of restenosis between carotid endarterectomy and carotid artery stenting in patients with atherosclerotic carotid stenosis. World Neurosurg. 2019; 125: 74–86, doi: 10.1016/j.wneu.2019.01.118, indexed in Pubmed: 30710719.

27. Dakour-Aridi H, Mathlouthi A, Locham S, et al. Predictors of midterm high-grade restenosis after carotid revascularization in a multicenter national database. J Vasc Surg. 2020; 71(6): 1972–1981, doi: 10.1016/j.jvs.2019.07.100, indexed in Pubmed: 32085958.

28. Ziapour B, Schermerhorn ML, Iafrati MD, et al. A systematic review and meta-analysis of predilation and postdilation in transfemoral carotid artery stenting. J Vasc Surg. 2020; 72(1): 346–355.e1, doi: 10.1016/j.jvs.2019.11.044, indexed in Pubmed: 32139309.

29. Achim A, Lackó D, Hüttl A, et al. Impact of diabetes mellitus on early clinical outcome and stent restenosis after carotid artery stenting. J Diabetes Res. 2022; 2022: 4196195, doi: 10.1155/2022/4196195, indexed in Pubmed: 35860343.

30. Yılmaz C, Güvendi Şengör B, Zehir R, et al. In-stent restenosis estimation following carotid artery stenting: The robust predictive value of atherogenic index of plasma and other non-traditional lipid profiles. Vascular. 2024: 17085381241249261, doi: 10.1177/17085381241249261, indexed in Pubmed: 38662526.

31. Kadoglou NPe, Khattab E, Velidakis N, et al. A new approach of statin therapy in carotid atherosclerosis: Targeting indices of plaque vulnerability on the top of lipid-lowering. A narrative review. Kardiol Pol. 2022; 80(9): 880–890, doi: 10.33963/KP.a2022.0155, indexed in Pubmed: 35734817.

32. Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med. 2018; 52: 8–12, doi: 10.1016/j.ejim.2018.04.014, indexed in Pubmed: 29680174.

33. Núñez J, Sanchis J, Bodí V, et al. Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levels. Atherosclerosis. 2009; 206(1): 251–257, doi: 10.1016/j.atherosclerosis.2009.01.029, indexed in Pubmed: 19230894.

34. Gurbuz O, Kumtepe G, Ozkan H, et al. Predictive value of neutrophil-lymphocyte ratio for long-term cardiovascular event following coronary artery bypass grafting. Braz J Cardiovasc Surg. 2020; 35(3): 274–284, doi: 10.21470/1678-9741-2018-0362, indexed in Pubmed: 32549098.

35. Leite JF, Antunes CF, Monteiro JC, et al. Value of nutritional parameters in the prediction of postoperative complications in elective gastrointestinal surgery. Br J Surg. 1987; 74(5): 426–429, doi: 10.1002/bjs.1800740538, indexed in Pubmed: 3594145.

36. Folkman S. Thoughts about psychological factors, PNI, and cancer. Adv Mind Body Med. 1999; 15(4): 255–281, doi: 10.1054/ambm.1999.0100, indexed in Pubmed: 10555396.

37. Cheng YL, Sung SH, Cheng HM, et al. Prognostic nutritional index and the risk of mortality in patients with acute heart failure. J Am Heart Assoc. 2017; 6(6): e004876, doi: 10.1161/JAHA.116.004876, indexed in Pubmed: 28649089.

38. Chen XL, Wei XB, Huang JL, et al. The prognostic nutritional index might predict clinical outcomes in patients with idiopathic dilated cardiomyopathy. Nutr Metab Cardiovasc Dis. 2020; 30(3): 393–399, doi: 10.1016/j.numecd.2019.10.007, indexed in Pubmed: 31791635.

39. Wang Z, Zhao L, He S. Prognostic nutritional index and the risk of mortality in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021; 331: 152–157, doi: 10.1016/j.ijcard.2021.01.023, indexed in Pubmed: 33529655.

40. Keskin M, İpek G, Aldağ M, et al. Effect of nutritional status on mortality in patients undergoing coronary artery bypass grafting. Nutrition. 2018; 48: 82–86, doi: 10.1016/j.nut.2017.10.024, indexed in Pubmed: 29469026.

41. Ma XT, Shao QY, Li QX, et al. Nutritional risk index improves the GRACE score prediction of clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Front Cardiovasc Med. 2021; 8: 773200, doi: 10.3389/fcvm.2021.773200, indexed in Pubmed: 34977188.

42. Öcal L, Küp A, Keskin M, et al. Prognostic significance of pre-procedural prognostic nutritional index in patients with carotid artery stenting. J Stroke Cerebrovasc Dis. 2020; 29(8): 104932, doi: 10.1016/j.jstrokecerebrovasdis.2020.104932, indexed in Pubmed: 32689619.